Evidence map›Paper›PMID 37303973›Full record

ArticleMolecular and clinical oncology2023

Pertuzumab as second‑ or later‑line therapy for human epidermal growth factor receptor 2‑positive metastatic breast cancer: A clinical experience.

Ewelina Biskup, Céline Montavon Sartorius, Andreas Müller, Cornelia Leo, Catrina Uhlmann Nussbaum, Elena Laura Georgescu Margarint, Daniel Koychev, Alexander Schreiber, Christian Taverna, David Thorn and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 2 countries.

Ewelina BiskupDepartment of Basic and Clinical Medicine, Shanghai University of Medicine and Health Sciences, Shanghai 201318, P.R. China.
Céline Montavon SartoriusDepartment of Medical Oncology and Breast Cancer Center, University Hospital Basel, Spitalstrasse 21, 4031 Basel, Switzerland.
Andreas MüllerCanton Hospital Winterthur (Med. Oncology), 8400 Winterthur, Switzerland.
Cornelia LeoDepartment of Gynecology, Canton Hospital Baden, 5404 Baden, Switzerland.
Catrina Uhlmann NussbaumDepartment of Internal Medicine, Canton Hospital Olten, 4600 Olten, Switzerland.
Elena Laura Georgescu MargarintShanghai East International Medical Center, Shanghai 200120, P.R. China.
Daniel KoychevTumor Center ZeTuP, 8640 Rapperswil, Switzerland.
Alexander SchreiberCanton Hospital Aarau, 5001 Aarau, Switzerland.
Christian TavernaCanton Hospital Muensterlingen, 8596 Münsterlingen, Switzerland.
David ThornOncology Private Practice Basel, Department of Medical Oncology, University Hospital Basel, 4052 Basel, Switzerland.
Marcus VetterMedical University Clinic, Canton Hospital Baselland, University of Basel, 4410 Liestal, Switzerland.
University Hospital of Basel · CHKantonsschule Olten · CHKantonsspital Aarau · CHKantonsspital Baden · CHKantonsspital Münsterlingen · CHKantonsspital Winterthur · CHShanghai International Medical Center · CNShanghai University of Medicine and Health Sciences · CNUniversity of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trastuzumab and pertuzumab with taxane-based chemotherapy are considered the first-line standard therapy for human epidermal growth factor receptor 2 (

Indexed as

human epidermal growth factor receptor 2metastatic breast canceroverall survivalpertuzumabsecond-line therapytrastuzumab

Identifiers

PMID37303973
PMCPMC10251341
OpenAlexW4377103786

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.